Scientists move in on genes conferring susceptibility, resistance to cancer

April 03, 2000

UCSF Comprehensive Cancer Center researchers have identified genetic regions in mice that confer susceptibility and resistance to a human-like skin cancer, suggesting, they say, that mouse studies may reveal genetic markers of susceptibility and resistance to cancer in humans.

The researchers also determined that several of the regions discovered are associated with survival time once cancer has developed -- the first such regions ever reported.

The findings will be presented at the American Association for Cancer Research meeting on Wednesday (April 5) in San Francisco. Some of the findings were published in December in Proceedings of the National Academy of Science.

The mice used in the UCSF study developed cancer the way humans do -- the tumors arose at the normally occurring site of the disease and had genetic alterations similar to those seen in human tumors. In contrast, in traditional mouse models of cancer, a malignant tumor that has been grown for years in culture is implanted under the skin of an immunodeficient mouse.

"These new models mimic natural conditions of cancer," says the senior author of the study, Allan Balmain, PhD, UCSF professor of biochemistry. "They reflect the growth rate of the tumor, the ability of the tumor to spread and metastasize -- they reflect everything you would see in humans."

Balmain's research program is part of a new consortium for studies of mouse models of tumors that recently received support from the National Cancer Institute. Three other UCSF research programs, as well as those at 15 other institutions, are also involved.

The identification of similar genetic markers in humans could directly impact the screening and assessment of cancers in humans. "Accurate prediction of tumor growth rate and survival time would be enormously beneficial in determining patient-specific treatment modalities, and could spare some patients surgery and many patients unnecessarily harsh exposure to cytotoxic therapeutic drugs," says Balmain.

Moreover, he says, "If we could predict who has which variants of these genes, we could proactively assess people for the likelihood of susceptibility to cancer and recurrent tumors through blood tests."

The researchers conducted their study in two species of mice - one, known as Mus musculus, has been inbred over many generations in the laboratory, so that all of the animals in any one strain are genetically identical; the second species, known as Mus spretus, is, by nature, highly resistant to tumor development in several organs, such as the lung, skin, liver and colon.

The investigators made hybrids between these two types of mice to track the genes responsible for making the spretus mice resistant to cancer. They exposed the two species to cancer-causing agents, and then used genetic mapping techniques to find regions of the genome that influence the number of benign tumors that formed, whether they progressed to malignancy, and at what rate.

The investigators identified ten genetic regions that significantly influenced tumor development. They also discovered a specific combination of a subset of the resistance-associated regions that was significantly associated with increased survival time once a malignant tumor developed.

"The study shows that some of these variants are very potent at preventing cancer," says Balmain. Most likely, he says, the genes involved control different aspects of the process leading to cancer, such as the growth rate of cells and the ability of tumors to grow blood vessels that will then provide them with the nutrients they need to grow.

Notably, the UCSF researchers have discovered that some of the genes that control the susceptibility to skin cancer are in the same positions in the mouse genome as those associated with susceptibility to colon and lung cancer. And this suggests, says Balmain, that there may be some "master" genes that control the development of multiple tumor types in different organs. Most likely there are also some genes that are tissue and organ specific.

The next step in the research, he says, is to move from the identification of the genetic regions to the genes themselves. From there, researchers could begin working to identify the proteins produced by these genes and the molecular chain of events - whether beneficial or harmful - that these proteins help to instigate. The final step would be developing drugs that either mimic or thwart this molecular outcome.

Significantly, the process of identifying individual genes in the mouse is becoming increasingly efficient, thanks to progress on sequencing the overall mouse genome. Comparing gene regions that confer susceptibility or resistance to cancer with a map that identifies each gene in the mouse genome will allow scientists to move in on the implicated genes more quickly. The sequencing of the mouse genome is expected to be completed within the next year.

Co-authors of the UCSF study are Hiroki Nagase, MD, formerly a visiting researcher in the UCSF Comprehensive Cancer Center, and Jian-Hua Mao, PhD, an associate specialist in the UCSF Comprehensive Cancer Center.

The study was funded by the Cancer Research Campaign (UK), Onyx Pharmaceuticals and the UCSF Comprehensive Cancer Center.
-end-


University of California - San Francisco

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.